Related references
Note: Only part of the references are listed.Inhibition of the CSF-1 receptor sensitizes ovarian cancer cells to cisplatin
Rong Yu et al.
CELL BIOCHEMISTRY AND FUNCTION (2018)
Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG 1406).
Scott Kopetz et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
BRAF-mutated cells activate GCN2-mediated integrated stress response as a cytoprotective mechanism in response to vemurafenib
Ikuko Nagasawa et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2017)
An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling (vol 30, pg 485, 2016)
Zoi Karoulia et al.
CANCER CELL (2016)
BRAF-Directed Therapy in Metastatic Colorectal Cancer
Krittiya Korphaisarn et al.
CANCER JOURNAL (2016)
Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma
Maria Romina Girotti et al.
CANCER CELL (2015)
Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: A meta-analysis
Filippo Pietrantonio et al.
EUROPEAN JOURNAL OF CANCER (2015)
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
David M. Hyman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
BRAF in metastatic colorectal cancer: the future starts now
Armando Orlandi et al.
PHARMACOGENOMICS (2015)
Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations
Leanne G. Ahronian et al.
CANCER DISCOVERY (2015)
Emerging insights into resistance to BRAF inhibitors in melanoma
Amanda D. Bucheit et al.
BIOCHEMICAL PHARMACOLOGY (2014)
Dabrafenib and Trametinib, Alone and in Combination for BRAF-Mutant Metastatic Melanoma
Alexander M. Menzies et al.
CLINICAL CANCER RESEARCH (2014)
BRAF Inhibitor Therapy for Melanoma, Thyroid and Colorectal Cancers: Development of Resistance and Future Prospects
Md Atiqur Rahman et al.
CURRENT CANCER DRUG TARGETS (2014)
BRAF inhibitor-associated ERK activation drives development of chronic lymphocytic leukemia
Niuscha Yaktapour et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
A Melanoma Cell State Distinction Influences Sensitivity to MAPK Pathway Inhibitors
David J. Konieczkowski et al.
CANCER DISCOVERY (2014)
Resistance to BRAF Inhibition in BRAF-Mutant Colon Cancer Can Be Overcome with PI3K Inhibition or Demethylating Agents
Muling Mao et al.
CLINICAL CANCER RESEARCH (2013)
Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3
Ethan V. Abel et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Discovery and Optimization of a Novel Series of Potent Mutant B-RafV600E Selective Kinase Inhibitors
Melissa M. Vasbinder et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Inhibiting EGF Receptor or SRC Family Kinase Signaling Overcomes BRAF Inhibitor Resistance in Melanoma
Maria R. Girotti et al.
CANCER DISCOVERY (2013)
Relief of Feedback Inhibition of HER3 Transcription by RAF and MEK Inhibitors Attenuates Their Antitumor Effects in BRAF-Mutant Thyroid Carcinomas
Cristina Montero-Conde et al.
CANCER DISCOVERY (2013)
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Anirudh Prahallad et al.
NATURE (2012)
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
Timothy R. Wilson et al.
NATURE (2012)
Vemurafenib: the first drug approved for BRAF-mutant cancer
Gideon Bollag et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF-Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib
Ryan B. Corcoran et al.
CANCER DISCOVERY (2012)
Phosphorylation of CSF-1R Y721 mediates its association with PI3K to regulate macrophage motility and enhancement of tumor cell invasion
Natalia G. Sampaio et al.
JOURNAL OF CELL SCIENCE (2011)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K
Jessie Villanueva et al.
CANCER CELL (2010)
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
Wendy De Roock et al.
LANCET ONCOLOGY (2010)
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikos I. Poulikakos et al.
NATURE (2010)
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
Georgia Hatzivassiliou et al.
NATURE (2010)
Melanomas acquire resistance toB-RAF(V600E) inhibition by RTK or N-RAS upregulation
Ramin Nazarian et al.
NATURE (2010)
Profiling Y561-Dependent and -Independent Substrates of CSF-1R in Epithelial Cells
Melodie L. Knowlton et al.
PLOS ONE (2010)
Immunodeficient Mouse Strains Display Marked Variability in Growth of Human Melanoma Lung Metastases
Beatriz M. Carreno et al.
CLINICAL CANCER RESEARCH (2009)
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Federica Di Nicolantonio et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells
Elisa Sala et al.
MOLECULAR CANCER RESEARCH (2008)
Extracellular signal-regulated kinase-dependent proliferation is mediated through the protein kinase A/B-Raf pathway in human uveal melanoma cells
A Calipel et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Autocrine CSF-1R activation promotes Src-dependent disruption of mammary epithelial architecture
CN Wrobel et al.
JOURNAL OF CELL BIOLOGY (2004)
Share Paper
